Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18645307 | 0.92 | DPP8 (0.51) | LTA4HATMDPP7SLC7A5CA12 | |
| SCHEMBL18644424 | 0.92 | DPP8 (0.51) | LTA4HATMDPP7SLC7A5CA12 | |
| SCHEMBL27878054 | 0.81 | LTA4H (0.55) | LTA4HSLC7A5KMT2AITGA4ITGB7 | |
| SCHEMBL2307682 | 0.81 | LTA4H (0.55) | LTA4HSLC7A5KMT2AITGA4ITGB7 | |
| SCHEMBL2307679 | 0.81 | LTA4H (0.55) | LTA4HSLC7A5KMT2AITGA4ITGB7 | |
| SCHEMBL7414508 | 0.81 | LTA4H (0.40) | LTA4HSLC7A5CA12CA1CA7 | |
| Hydrochloric Acid SCHEMBL29264506 | 0.80 | LTA4H (0.54) | LTA4HSLC7A5KMT2AITGA4ITGB7 | |
| SCHEMBL18644425 | 0.80 | ATM (0.49) | ATMCA12CA1CA7CA14 | |
| SCHEMBL15989154 | 0.79 | GRIK1 (0.55) | LTA4HSLC7A5CTSK | |
| SCHEMBL7077555 | 0.79 | GRIK1 (0.55) | LTA4HSLC7A5CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0731807-B1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030203862-A1 | Antisense modulation of MDM2 expression | ISIS PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| WO-2003048315-A2 | ANTISENSE MODULATION OF MDM2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6166199-A | N-2 substituted purines | ISIS PHARMACEUTICALS, INC (US) | 2000-12-26 | — | — | US | disclosed |
| US-5808027-A | ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0731807-A4 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS INC (US) | 1997-11-19 | — | — | EP | disclosed |
| US-5587469-A | USEFUL AS ?ANTISENSE AGENTS? THAT ARE CAPABLE OF SPECIFIC HYBRIDIZATION WITH A NUCLEOTIDE SEQUENCE OF AN RNA | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0731807-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995014707-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203862-A1 | Antisense modulation of MDM2 expression | MDM2, TP53, DCLRE1B | LTA4H 4349/4885ATM 1931/4885DPP7 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.